



ANNUAL REPORT 2021-22



CONTENTS

Corporate Governance Report.....	3-7
Directors' Report & Annexures.....	8-20
Auditors' Report.....	21-27
Balance Sheet.....	28
Profit & Loss Account.....	29
Cash Flow Statement.....	30
Notes on Financial Statement.....	31-47

CORPORATE INFORMATION

BOARD OF DIRECTORS

Chairman & Managing Director	Dr. Ajay P. Thakker
Executive Director	Dr. Ankit Thakker
Non-Executive Director's	Dr. Bhaskar Shah Mr. Devang Gandhi Dr. Navinchandra Davda Mr. Nitin Thakker Mr. Rajesh Vora Mr. V. Raghavan
Independent Director	Dr. Jasmin Patel
Independent Director	Dr. Darshan Vora

SENIOR LEADERSHIP

Chief Executive Officer	Dr. Ankit Thakker
Chief Financial Officer	Mr. Harshad Purani
Company Secretary	Mrs. Suma V Upparatti
Auditors	B.R. Kotecha & CO. 3104, Tower 4, Valentine, Runwal Anthurium LBS Road, Op. Veena Nagar, Mulund (W), Mumbai 400 080. Tel: +91 22 2592 5227
Bankers	ICICI Bank Ltd. Axis Bank Ltd. HDFC Bank Ltd.
Registered Office	1004, 10th floor, '360 Degree Business Park', Maharana Pratap Chowk, LBS Marg, Mulund (W), Mumbai - 400 080. CIN: U85100MH2002PLC137908 Tel: +91 22 2172 5555 Fax: +91 22 2545 3320 Email: info@jupiterhospital.com Web Site: www.jupiterhospital.com
Administration Office	Jupiter Hospital Eastern Express Highway, Thane (W) 400 061 Tel: +91 22 2172 5555 Fax: +91 22 2545 3320
Registrar & Transfer Agents	KFin Technologies Private Limited Selenium Tower B, Plot No 31 & 32, Financial District, Nanakramguda, Serilingampally Mandal, Hyderabad – 500 032 Toll Free Number: -1-800-309-4001 Email: einward.ris@kfintech.com www.kfintech.com

REPORT ON CORPORATE GOVERNANCE

Our Company Being Unlisted Public Company a report on Corporate Governance, in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and amendments thereto not needed to comply.

COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE

The company has always been committed to the principles of Good Corporate Governance which helps enhancement of long term shareholder value and their interest. This is achieved through increased awareness for responsibility, transparency and professionalism and focus for effective control and management of the organization. The Board of Directors of the Company is committed to adopt the best practices of corporate governance code keeping in view getting listed company in near future and this constant review of the Board processes, practices and the management systems is to maintain a greater degree of responsibility and accountability.

BOARD COMPOSITION

COMPOSITION AND SIZE OF THE BOARD AS ON 31ST MARCH, 2022 ARE GIVEN BELOW:

The Board of Directors, along with its Committees, provides leadership and guidance to the management and directs and supervises the performance of the Company, thereby enhancing stakeholder value. The Board has a fiduciary relationship in ensuring that the rights of all stakeholders are protected. Your Company has an engaged and well informed Board with qualifications and experience in diverse areas. The Board composition is in conformity with the Companies Act, 2013 ('the Act').

The Board of Directors, as on 31st March, 2022, comprises of 10 (Ten) Directors, 8 (Eight) are Non-Executive Directors of which 2 (Two) are Independent Director, 2 (Two) are Executive Director. All Directors possess relevant qualifications and experience in general corporate management, finance, banking and other allied fields which enable them to effectively contribute to the Company in their capacity as Directors.

Name of Director	Designation	Category	Board	Committees			
				Audit	Nomination & Remuneration	Corporate Social Responsibility	Investor Relations
Dr. Ajay P. Thakker	Chairman & Managing Director	ED & Promoter	C MAN	-	-	-	-
Dr. Ankit Thakker	Executive Director & CEO	ED	M	-	-	-	-
Dr. Bhaskar Shah	Director	NE	M	M	C MAN	C MAN	M
Mr. Devang Gandhi	Director	NE	M	-	-	-	-
Dr. Navinchandra Davda	Director	NE	M	-	-	-	-
Mr. Nitin Thakker	Director	NE	M	C MAN	M	M	C MAN
Mr. Rajesh Vora	Director	NE	M	M	M	M	M
Mr. V. Raghavan	Director	NE	M	-	-	-	-
Dr. Jasmin Patel	Director	INED	M	M	M	M	M
Dr. Darshan Vora	Director	INED	M	M	M	M	M

C MAN - Chairman, M - Member ED- Executive Director, INED - Independent Non-Executive Director, NE – Non Executive Director

None of the Directors on the Board is a Member of more than 10 Committees and Chairperson of more than 5 Committees (Committees being Audit Committee and Stakeholders Relationship Committee), across all the Companies in which they are Director. The necessary disclosures regarding committee positions have been made by all the Directors.

None of the Directors hold office in more than 20 Companies and in more than 10 public Companies. None of the Independent Directors serve as an Independent Director in more than seven listed Companies. The Managing Director does not serve as Independent Director in any listed Company.

Category and Attendance of Directors

The names and categories of Directors, their attendance at the Board Meetings held during the year and at the last Annual General Meeting, as also the number of Directorships and Committee positions held by them in Public Limited Companies are given below:

Name	DIN	Number of directorship held in other companies**	Number of Committee positions held in other companies ***		Attendance at	
			Chairman	Member	Board Meeting	Last AGM 29/09/2021
Dr. Ajay P. Thakker	00120887	8	None	None	5	Yes
Dr. Ankit Thakker	02874715	4	None	None	5	Yes
Dr. Bhaskar Shah	00007817	6	None	None	5	No
Mr. Devang Gandhi	00319483	3	None	None	4	Yes
Dr. Navinchandra Davda	00119826	2	None	None	5	No
Mr. Nitin Thakker	00134554	12	None	None	4	Yes
Mr. Rajesh Vora	00317240	5	None	None	4	Yes
Mr. V. Raghavan	00008182	1	None	2	5	No
Dr. Jasmin Patel	07261550	1	None	2	5	No
Dr. Darshan Vora	08207080	-	None	None	5	Yes

** Directorship, held by Directors as mentioned above includes LLP; do not include directorships in foreign companies.

*** This includes the Chairmanships/ Membership only in the Audit Committee and Shareholders' Grievance Committee of all listed and unlisted public limited companies (excluding Jupiter Life Line Hospitals Ltd.) have been considered.

Relationship between Directors inter-se

None of the Directors are related inter-se except Dr. Ajay P. Thakker and Dr. Ankit Thakker who are relative of each other.

BOARD COMMITTEES MEETING:

Details of the Board Committees meeting and other related information are provided hereunder:

Name	No. of Committee Meeting held and attended during the year				
	Audit	CSR	Nomination & Remuneration	Investor Relations	Independent Director
No. of Committee Meeting held during the year	4	4	4	4	1
Mr. Nitin Thakker	3	3	3	3	-
Dr. Bhaskar Shah	4	4	4	4	-
Mr. Rajesh Vora	3	3	3	3	-
Dr. Jasmin Patel	4	4	4	4	1
Dr. Darshan Vora	4	4	4	4	1

BOARD MEETINGS:

Board Meetings are held at least once in every quarter. The time gaps between two meetings were not more than one hundred and twenty days. There were five Board Meetings held during the Financial Year from 1st April, 2021 to 31st March, 2022 viz. on 15/06/2021, 12/08/2021, 21/09/2021, 21/12/2021 and 08/03/2022.

The Board is regularly apprised and informed of important business related information. The agenda papers are circulated in advance to all the Board members through email. The quarterly results of the company, the annual plan and budgets, capital budgets etc. are placed before the Board as and when required. The minutes of Board Meeting, Remuneration Committee Meeting, Audit Committee Meeting, Investor Relation Committee Meeting and General Meeting are circulated and placed before the board at regular interval.

Independent Director:

As per provision of section 149 and schedule IV of Companies Act, 2013, the Independent Director of the Company has Separate meetings on 08/03/2022 in the presence of both the Independent Director Dr. Jasmin Patel and Dr. Darshan Vora. The meeting was held to (a) review the performance of non-independent directors and the Board as a whole; (b) review the performance of the Chairperson of the company, taking into account the views of executive directors and non-executive directors; (c) assess the quality, quantity and timeliness of flow of information between the company management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

AUDIT COMMITTEE

Pursuant provision of Section 177 and applicable Rules of the Companies Act, 2013, the Audit Committee Meeting was held on 15/06/2021, 12/08/2021, 21/12,2021 and 08/03/2022.

Role of the Audit Committee, inter alia, includes the following:

- i) The recommendation for appointment, remuneration and terms of appointment of auditors of the company.
- ii) To review and monitor the auditor's independence and performance, effectiveness of the audit process.
- iii) To examine the financial statements and the audit report thereon.
- iv) To approval or any subsequent modification of transactions of the company with related parties.
- v) To scrutiny of inter-corporate loans and investments.
- vi) To valuate of undertakings or assets of the company, wherever it is necessary.
- vii) To evaluate internal financial controls and risk management systems.
- viii) To monitor end use of funds raised through public offers and related matters.
- ix) To review and discuss with the management, the performance of statutory auditors and internal auditors, adequacy of internal control systems, scope of audit, including the observations of the auditors and review of financial statement before their submission to the Board.
- x) To investigate into any matter and to have full access to information contained in the records of the company.
- xi) To obtain professional advice from external source, if required.
- xii) To review functioning of vigil mechanism/Whistle Blower Policy.

All the recommendation of the Audit committee has been accepted by the Board.

NOMINATION AND REMUNERATION AND INVESTORS RELATIONSHIP COMMITTEE

Pursuant to provision of section 178 and applicable rules of Companies Act, 2013. The Nomination and Remuneration Committee and Investors Relationship committee were formulated.

The Nomination and Remuneration Committee meeting was held on 15/06/2021, 12/08/2021, 21/12,2021 and 08/03/2022 during the year and reviewed the matters relating to Remuneration during the Financial Year 2021-2022.

The terms of reference of the committee, inter alia, includes the following:

- i) To identify persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, recommend to the Board their appointment and removal and shall carry out evaluation of every director's performance.
- ii) To formulate the criteria for determining qualifications, positive attributes and independence of a director and recommend to the board a policy, relating to the remuneration for the directors, key managerial personnel and other employees.
- iii) The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate directors of the quality required to run the company successfully,

- iv) Relationship of remuneration to performance is clear and meets appropriate performance benchmark and
- v) Remuneration to directors, key managerial personnel and senior management involves a balance between fixed and incentive pay reflecting short and long term performance objectives appropriate to the working of the company and its goals.

As per provision of section 178 (5) of Companies Act, 2013, the company is not having more than one thousand shareholders, debenture holders, deposit holders and any other security holders at any time during a financial year. Hence proviso of section 178 (5) is not applicable.

The company is having investor relationship committee.

The terms of reference include redressal of complaints from shareholders such as annual report, transfer of shares, issue of duplicate share certificate, etc. and monitor transfers, transmissions, dematerialisation, rematerialisation, splitting and consolidation of shares. The investor relation committee meeting was held on 15/06/2021, 12/08/2021, 21/12,2021 and 08/03/2022 reviewed that the Company has not received any oral/ written enquires from shareholders.

CORPORATE SOCIAL RESPONSIBILITY COMMITTEE

Formation of committee:

Pursuant to Section 135 of the Companies Act, 2013 the company has constituted the Corporate Social Responsibility (CSR) Committee of the Board of Directors.

The terms of reference of CSR Committee, inter alia, includes the following:

- i) To formulated and recommend to the board, a Corporate Social Responsibility policy which shall indicate the activities to be undertaken by the company as specified in Schedule VII.
- ii) To recommend the amount of expenditure to be incurred on the activities.
- iii) To monitor the Corporate Social Responsibility policy of the company from time to time.

The Annual Report of CSR activities are as follows:

CSR Committee

The CSR Committee of the board is responsible for overseeing the execution of the Company's CSR policy. The CSR committee comprises two independent Directors and three non-executives Director. The members of CSR committee are provided under composition of Board committees.

CSR Meeting

The CSR committee meeting was held on 15/06/2021, 12/08/2021, 21/12,2021 and 08/03/2022.

Financial details

In pursuant to Section 135 of the Companies Act, 2013 the company has constituted the Corporate Social Responsibility (CSR) Committee of the Board of Directors. The terms of reference of CSR Committee are as per the provisions of the Companies Act, 2013 The detail has been disclosed in the Annual Report on CSR Activities forms an integral part of Annexure to Director Report.

Committee responsibility

The committee hereby affirms that the CSR policy is in compliance with the CSR objectives and policy of the Company.

VIGIL MECHANISM/WHISTLER BLOWER POLICY

The company promotes ethical behavior in all its business activities and has put in place a mechanism for reporting illegal or unethical behavior. The company has a vigil mechanism under which employees and directors are free to report violation of applicable laws and regulations to the Chairman of Audit Committee. During the F.Y. 2021-2022, the company has not received any complaints under this mechanism

GENERAL BODY MEETING

Details of last three years General Meeting are as under:

Financial Year (ended)	Day, Date and Time of AGM	Venue	Special Resolution passed
31 st Mar, 2021 19 th AGM	Wednesday 29 th Sep, 2021 At 10.00 a.m.	1004, 10th Floor, 360 Degree Business Park, Maharana Pratap Chowk, L.B.S. Marg, Mulund (W), Mumbai - 400 080	Five Special Resolution
31 st Mar, 2020 18 th AGM	Wednesday 23 rd Sep, 2020 At 11.30 a.m.	1004, 10th Floor, 360 Degree Business Park, Maharana Pratap Chowk, L.B.S. Marg, Mulund (W), Mumbai - 400 080	No Special Resolution
31 st Mar, 2019 17 th AGM	Tuesday, 24 th Sep, 2019 At 11.00 a.m.	1004, 10th Floor, 360 Degree Business Park, Maharana Pratap Chowk, L.B.S. Marg, Mulund (W), Mumbai - 400 080	Five Special Resolution

DISCLOSURES

There were no materially significant related party transactions i.e. transactions of the company of material nature, with its Promoters, the Directors or the Management, their relatives etc. that may have potential conflict with the interest of the company at large except mentioned in the notes to the Accounts.

During the last three years there were no penalties imposed on the company by any Statutory Authority.

GENERAL SHAREHOLDER INFORMATION
I) Company Registration Details

The company is registered in the State of Maharashtra, India. The Corporate Identity Number (CIN) allotted to the company by the Ministry of Corporate Affairs (MCA) is U85100MH2002PLC137908.

II) Company ISIN Details

The company is registered with National Securities Depository Limited. The International Securities Identification Number (ISIN) allotted to the company by NSDL is INE682M01012 and INE682M13017.

III) Dematerialisation of shares as on 31st March, 2022

Sr. No	Mode of Holding	% age
1	NSDL	95.55
2	Physical	0.45
	Total	100.00

IV) Annual General Meeting (Day, Date, Time and Venue):

Thursday, 8th September, 2022 at 11.30 a.m.

to be held at registered Office

1004, 10th floor, '360 Degree Business Park', Maharana Pratap Chowk, LBS Marg, Mulund (W), Mumbai - 400 080.

V) Registrar and Transfer Agents:

KFin Technologies Private Limited

Karvy Selenium Tower B, Plot No 31 & 32, Gachibowli, Financial District, Nanakram guda, Serilingampally, Hyderabad – 500 032 Tel: +91 40 6716 1500, Fax: +91 40 2342 0814, Email: chandrasekhar.r@karvy.com, www.kfintech.com.

VI) Date of Book Closure:

Wednesday, 24th August, 2022 to Wednesday, 7th September, 2022 (both day inclusive) for list of shareholders as on Annual General Meeting day.

DIRECTORS' REPORT

Dear Members,

The Board of Directors is pleased to present the 20th Annual Report of the Company for the financial year ended 31st March, 2022.

FINANCIAL RESULTS, OPERATIONS AND STATE OF AFFAIRS OF THE COMPANY:

The financial performance of the company, for the year ended 31st March, 2022 is summarized below:

Rs. In Lakhs

	Standalone		Consolidated	
	2021-2022	2020-2021	2021-2022	2020-2021
Revenue from Operation	65,727.85	46,109.55	73,312.27	48,616.37
Other Income	375.45	402.88	402.12	410.58
TOTAL REVENUE A	66,103.30	46,512.43	73,714.39	49,026.95
Purchases of stock in trade	12,841.76	9,185.84	14,453.52	9,753.45
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(177.43)	243.08	(231.26)	90.80
Employee Cost	11,690.00	10,039.96	13,378.04	10,596.74
Finance Cost	2,923.37	2,817.00	4,393.60	3,897.60
Other expenses	25,488.47	19,733.35	30,373.14	21,459.20
TOTAL EXPENDITURE B	52,766.17	42,019.23	62,367.04	45,797.79
PBDT (A-B)	13,337.13	4,493.20	11,347.35	3,229.16
Less: Depreciation and amortization expense	2,765.87	2,738.28	3,615.73	3,073.69
PROFIT BEFORE TAX	10,571.25	1,754.92	7,731.62	155.47

COVID-19 AND ITS IMPACT:

During the year due to COVID 19 pandemic situation and restrictions announced by Government of India the Company has huge impact in its financials. Even though increase of manpower and purchase cost due to COVID, the Company has maintained healthy growth in financials and profit. The Company has increased its expenditure for safety and welfare of its staff and medical teams.

ANNUAL RETURN:

The extracts of Annual Return pursuant to the provisions of section 92 read with Rule 12 of the companies (Management and Administration) Rules, 2014 for FY 2021-22 is furnished in Annexure 2 and is attached to this Report.

Any shareholder interested in obtaining the same may write to the Company Secretary at the Registered Office of the Company. The said information is available for inspection by the Members at the Registered Office of the Company on any working day of the Company upto the date of the 20th Annual General Meeting.

NUMBER OF MEETINGS OF THE BOARD:

Board Meetings are held at least once in every quarter. The time gaps between two meetings were not more than one hundred and twenty days. There were five Board Meetings held during the Financial Year from 1st April, 2021 to 31st March, 2022 viz. on 15/06/2021, 12/08/2021, 21/09/2021, 21/12/2021 and 08/03/2022.

The Board is regularly apprised and informed of material business-related information. The agenda papers are circulated in advance to all the Board members. The quarterly results of the company, the annual plan and budgets, capital budgets etc. are placed before the Board, as and when required.

GENERAL MEETING:

The Company has held its Annual General Meeting on 29th September, 2021.

DIVIDEND:

The Board of Directors has recommended 10% dividend for the financial year ended 31st March, 2022.

TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND:

The company is not declared any dividend last year and there was no dividend unpaid / unclaimed as per provisions of section 125 of the Companies Act, 2013.

BOARD DIVERSITY:

The Company recognizes and embraces the importance of a diverse board in its success. The Company believes that a truly diverse board will leverage difference in thought, perspective, knowledge, skill and industry experience that will help the Company to retain the competitive advantage.

DIRECTORS AND KMP:

REAPPOINTMENTS:

In pursuant to the provisions of section 152 of the Companies Act, 2013 Dr. Navinchandra Davda (DIN: 00119826), Mr. V Raghavan (DIN: 00008182) and Mr. Rajesh Vora (DIN: 00317240) of the Company retire by rotation at the ensuing Annual General Meeting and being eligible, offer themselves for reappointment. Based on the performance evaluation and recommendation of the nomination and remuneration committee, the board recommends their reappointment.

COMPANY'S POLICY RELATING TO DIRECTORS APPOINTMENT, PAYMENT OF REMUNERATION AND DISCHARGE OF THEIR DUTIES:

The Company policy is to have an appropriate mix of executive and non-executive and independent Directors to maintain the independence of the board, and separate its functions of governance and management. As on 31st March, 2022, the Board has ten members, two of whom are executive directors and two of them are independent Director and others are non-executive director. One of the independent directors of the board is Women Director.

The provision of section 178 (1) is applicable to the company and hence the company has formed proper policy on directors' appointment, payment of managerial remuneration, directors' disqualifications, positive attributes, independence of directors and other related matters as provided under section 178(3) of the Companies Act, 2013. The said policy of Nomination and Remuneration Committee is disclosed in Corporate Governance.

DECLARATION OF INDEPENDENT DIRECTORS:

The Company has received necessary declaration from each independent Director under Section 149(7) of the Companies Act, 2013, that he / she meets the criteria of independence as stipulated in section 149 (6) of the Companies Act, 2013 and qualify themselves as Independent Directors under the provisions of Companies Act, 2013 and relevant rules.

BOARD EVALUATION:

In pursuant to the requirement of Section 134 (p) of the Companies Act, 2013, state that a formal annual evaluation needs to be made by the Board of its own performance and that of its committees and individual directors. The performance evaluation of all directors including Independent Director was reviewed by the Board on annual basis. The Directors expressed their satisfaction with the overall evaluation.

MATERIAL CHANGES AND COMMITMENT IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR TO WHICH THIS FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT:

No material changes and commitments affecting the financial position of the company occurred between the end of the financial year to which this financial statements relate on the date of this report.

EXPLANATION OR COMMENTS ON QUALIFICATIONS, RESEVATIONS OR ADVERSE REMARKS OR DISCLAIMERS MADE BY THE AUDITORS AND THE PRACTICING COMPANY SECRETARY IN THEIR REPORT:

The Auditors Report for the F.Y. 2021-2022 does not contain any qualification, reservation or adverse remark. The Auditors report is enclosed with the financial statements in this Annual Report.

I) STATUTORY AUDITORS:

Under section 139 of the Companies Act, 2013 and the Rules made thereunder, B.R Kotecha & Co, Chartered Accountants (Firm Registration No. 105283W), Mumbai, has completed his tenure of five years as a Statutory Auditors of the Company in forthcoming 20th Annual General Meeting.

The Notes on financial statements referred to in the Auditors' Report are self-explanatory and do not call for any further comments. The Auditor in their report has not made any qualifications, reservations or adverse remarks for the Financial Year 2021-2022.

Subject to approval of members in the ensuing Annual General meeting the Board of Director and Audit Committee has recommended to appoint M/s. Aswin Malde & Co. bearing Membership No.032662, Chartered Accountant, Mumbai as the statutory auditor of the company to hold the office from the conclusion of ensuing Annual General Meeting up to the conclusion of 25th Annual General Meeting i.e. for the period of five years on such remuneration as may be decided by the Board, with reference to provisions of Section 139 and other applicable provision read with Companies (Audit and Auditors) Rules, 2014, of the Companies Act, 2013, (including any statutory modifications, amendments or re-enactments thereof for the time being in force).

II) COST AUDITOR:

The Board of Directors, in pursuance to section 148 of the Companies Act, 2013, has appointed M/s. V. J. Talati & Co., Cost Accountant Firm (Membership No. M/26963), Mumbai, for conducting the audit of the cost accounting records maintained by the company for the Financial Year 2022-2023 subject to shareholder's approval. The Cost Auditors have certified that their appointment was within the limits of Section 141(3) (g) of the Companies Act, 2013 and that they are not disqualified from appointment within the meaning of the said Act.

The Auditor in their report has not made any qualifications, reservations or adverse remarks for the Financial Year 2021-2022.

III) SECRETARIAL AUDITOR:

As required under Section 204 of the Companies Act, 2013 and Rules thereunder, the Board has appointed B. L. Tanna & Co., Practising Company Secretary (CP No. 2419), to conduct Secretarial Audit. The Secretarial Audit Report for the financial year ended 31st March, 2022 is annexed herewith marked as Annexure 1 to this Report. The Secretarial Audit Report does not contain any qualification, reservation or adverse remark.

IV) INTERNAL AUDITOR:

As required under section 138 of the Companies Act, 2013 and its Rules thereunder, the Board has appointed in consultation with Audit Committee M/s Gala & Associate (Firm Registration No: 120731W), Prop. Ashwin M Gala (Membership No. 041323), Chartered Accountants as Internal Auditor of the company. The Internal Auditor does not contain any qualification, reservation or adverse remark.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE UNDER SECTION 186 OF THE COMPANIES ACT, 2013:

Loans, guarantees or investments covered under Section 186 of the Companies Act, 2013 form part of the Notes to the financial statements provided in this Annual Report.

PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES:

All contract / arrangements / transactions entered by the Company during the financial year with related parties were in ordinary course of business and on an arm's length basis. The related party contracts / arrangement / transactions are disclosed in financial statement in Note 35.

TRANSFER TO RESERVES:

The company proposes to transfer Rs. 846.71 Lakhs to the General Reserve out of amount available for appropriation, and an amount of Rs. 6528.10 Lakhs is proposed to be retained in profit and loss account.

PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES:

Disclosures pertaining to remuneration and other details of employee as required under Rule 5(2) of the Companies (Appointment and Remuneration of Managerial personnel) Rules, 2014:

- a. Information as required by the provisions of Rule 5 (2) (i) of the Companies (Appointment and Remuneration of Managerial Personnel) Amendment Rules, 2016, regarding particulars of employees drawing Rs. 1,02,00,000/- per annum is Dr. Ajay P Thakker CMD of the Company, who has drawn salary of Rs.1,80,00,000/- during the year. Dr. Ankit Thakker Executive Director and CEO, who has drawn salary of Rs. 1,20,00,000/- and Dr. Rajendra P Patankar, Pune unit CEO, who has drawn salary of Rs. 1,07,75,177/-.
- b. Information as required by the provisions of Rule 5 (2) (ii) of the Companies (Appointment and Remuneration of Managerial Personnel) Amendment Rules, 2016, regarding particulars of employees drawing Rs. 8,50,000/- per month is NIL.
- c. Information as required by the provisions of Rule 5 (2) (iii) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, regarding particulars of employees drawing remuneration in excess of that drawing by the Managing Director or Whole Time Director or Manager and hold by himself or along with his/her spouse and dependent children, not less than two percent., of the equity shares of the Company is NIL.

DISCLOSURES:

All disclosures relating to Audit Committee, Nomination and Remuneration and Investors Relationship Committee, Corporate Social Responsibility Committee and Vigil Mechanism/ Whistle Blower policy and Independent Director meeting are disclosed under Corporate Governance.

RISK MANAGEMENT POLICY:

The company does not have any risk management policy as the elements of risk threatening the company's existence.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS:

There are no significant or material orders which were passed by the Regulators or Courts or Tribunals which impact the going concern status and the Company's Operations in future.

SECRETARIAL STANDARD:

The Company complies with all applicable mandatory secretarial standards issued by the Institute of Company Secretaries of India.

CREDIT RATING:

The Company has obtained ratings from CARE Ratings Limited reaffirmed the Long term bank facilities of A- stable during the year ended 31st March, 2022.

FIXED DEPOSIT:

The Company has not accepted any fixed deposits and no amount of principal or interest is outstanding during the year ended 31st March, 2022.

REPORTING OF FRAUDS BY AUDITORS:

During the year under review, neither statutory Auditors nor the secretarial auditor has reported to the audit committee, under section 143(12) of the Companies Act, 2013, any instances of fraud committed against the Company by its officers or employees, the details of which would need to be mentioned in the Board's Report.

SUBSIDIARIES:

The Company has invested in Jupiter Hospital Projects Pvt. Ltd. the subsidiary Company by holding its 76% of equity share and 100% optionally convertible redeemable preference share (OCRPS) during the year. During the year, the Board of Directors reviewed the satisfactory affairs of the subsidiary Company. In accordance with Section 129(3) of the Companies Act, 2013, the Company has prepared the consolidated financial statements of the Company. Further, a statement containing the salient features of the financial statement of subsidiary in the prescribed format AOC -1 is appended as annexure 3 and forms the integral part of this report. The statement also provides details of the performance and financial position of the subsidiaries.

PARTICULARS AS REQUIRED U/S 314(3)(m) OF THE COMPANIES ACT, 2013:
a. Conservation of energy:

The Company has capital investment on three wind turbine generator, the energy conservation equipment at Nandurbar, Maharashtra. The turbine generator helps to reduce the overall cost of consumption of energy in its both the units Thane and Pune. The Company is in process of purchase of one more turbine generator at Sangali, Maharashtra.

b. Technology Absorption: NIL
Foreign Exchange Earnings / Outgo:

Current year details are as follows:	
Revenue from Hospital	Rs. 232.63 Lakhs *
Revenue from Hotel	Rs. 48.93 Lakhs **
Total Foreign earnings	Rs. 281.56 Lakhs
Foreign Exchange Outflow (Imports of capital goods)	NIL
Foreign Exchange Outflow (Expenses)	Rs. 10.17 Lakhs

* In the Books of Accounts Rs. 281.56 Lakhs is incorporated in Foreign Income A/c which is included in Revenue from Hospital Operations.

** Rs. 48.93 Lakhs included in collection of Fortune Park Lake City, Thane.

CORPORATE SOCIAL RESPONSIBILITY:

The company firmly believes that, industry owes duty of welfare to the society at large and it shall pursue the commitment of social responsibility and carry out and support structure to empower the less privileged sections of society in Education and Health Care activities.

In pursuant to Section 135 of the Companies Act, 2013 the company has constituted the Corporate Social Responsibility (CSR) Committee of the Board of Directors. The terms of reference of CSR Committee are as per the provisions of the Companies Act, 2013. The detail has been disclosed in the Annual Report on CSR Activities for 2021-22 as required under the Companies (Corporate Social Responsibility Policy) Rules, 2014 has been appended as Annexure 4 and forms an integral part of this report.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has in place an Anti-Sexual Harassment policy in line with the requirements of the Sexual Harassment of women at the workplace (Prevention Prohibition & Redressal) Act, 2013. Prevention of Sexual Harassment (POSH) has been set up to redress complaints received regarding sexual harassment. All employees (permanent, temporary, trainees) are covered under this policy.

The following is a summary of Sexual Harassment complaints received and disposed off during each calendar year.

No. of Complaints received :NIL

No. of Complaints disposed off :NIL

During the year no allegations of sexual harassment was filed with the Company.

DIRECTORS' RESPONSIBILITY STATEMENT:

In pursuant to the requirement u/s 134 (3) (c) of the Companies Act, 2013, the Board of Directors confirms:

- a. That in the preparation of the annual accounts for the financial year ended 31st March, 2022, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- b. That the Directors have selected such accounting policies and applied consistently and made judgments and estimates that were reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that period;
- c. That the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d. That the Directors have prepared the annual accounts on a going concern basis.
- e. That the Directors have laid down internal financial controls in the Company that are adequate and were operating effectively.
- f. That the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

ACKNOWLEDGEMENT:

We thank our Shareholders, Auditors, Patients, Medical Professionals, Employees, Service Providers and Vendors for their continued support and co-operation during the year. The company wish to place on record the whole hearted support and sincere co-operation received from its bankers, ICICI Bank limited, Axis Bank Limited, HDFC Bank Limited, Axis Trustee Services Ltd., State Bank of India and The Thane Janata Sahakari Bank Ltd. and various Government agencies.

For and on behalf of the Board

04/07/2022

Sd/-

Mumbai

Dr. Ajay P. Thakker
Chairman & Managing Director
DIN: 00120887

Secretarial Audit Report

For the financial year ended 31st March 2022

[Pursuant to section 204(1) of the Companies Act, 2013 and Rule No.9
of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To

The Members

Jupiter Life Line Hospitals Limited

1004, 10th Floor, 360 Degree Business Park,

Maharana Pratap Chowk, L.B.S. Marg,

Mulund (W), Mumbai - 400 080

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Jupiter Life Line Hospitals Limited** (hereinafter called "the Company"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in our opinion, the company has, during the audit period covering the financial year ended on 31st March, 2022, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanisms in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March, 2022 according to the provisions:

- i) The Companies Act, 2013 ("the Act") and the rules made there under;
- ii) The Securities Contracts (Regulation) Act, 1956 (SCRA) and the rules made there under;
- iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
- iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of External Commercial Borrowings;

I have also examined compliance with the applicable clauses of Secretarial Standards issued by The Institute of Company Secretaries of India.

During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines and Standards as mentioned above except The Company has during the year advanced interest free loans and has provided securities to its Subsidiary Company.

I further report that, having regard to the compliance system prevailing in the Company and on examination of the relevant documents and records in pursuance thereof, the company's management has identified and confirmed the following laws as being specifically applicable to the company.

1. Birth and Death and Marriage Registrations Act, 1886
2. Blood Bank Regulations under Drugs and Cosmetics Act, 1940
3. Clinical Thermometers (Quality Control) Order, 2001
4. Drugs and Cosmetics Act, 1940
5. Drugs and Cosmetics Rules, 1945
6. Epidemic Diseases Act, 1897
7. Excise Permit (For Storage of Spirit) under Central Excise Act, 1956
8. Legal Metrology Act, 2009

9. Legal Metrology Rules, 2011
10. Medical Termination of Pregnancy Act, 1971
11. Medical Termination of Pregnancy Regulations, 1976
12. Medical Termination of Pregnancy Rules, 1975
13. Narcotic Drugs and Psychotic Substances Act and Rules, 1985
14. Pharmacy Act, 1948
15. Pre Conception and Prenatal Diagnostic Techniques Act, 1994
16. Pre Conception and Prenatal Diagnostic Techniques Rules, 1996
17. The Bio Medical Waste (Management and Handling) Rules, 1998
18. Transplantation of Human Organs Act and Rules, 1994
19. Clinical Establishments and Registration Act, 2010/ State Private Clinical Establishment Registration Act.
20. Employee Provident Fund & Miscellaneous Provisions Act, 1962
21. Employee State Insurance Act, 1948
22. Employers Liability Act, 1938
23. Equal Remuneration Act, 1976
24. Maternity Benefits Act, 1961
25. Minimum Wages Act, 1948
26. Payment of Bonus Act, 1965
27. Payment of Gratuity Act, 1972 and other Labour Laws.

During the period under review the company has generally, complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards Etc. as mention above.

I further report, that the compliance by the Company of applicable financial laws, such as direct and indirect tax laws, has not been reviewed in this Audit since the same have been subject to review by the statutory financial auditor and other designated professionals.

I further report that:

The Board of Directors of the Company is generally well constituted with a proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were delivered and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meetings and for meaningful participation at the meetings.

All decisions at Board Meetings and Committee Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committee of the Board, as the case may be.

I further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

For B L Tanna & Co.

Sd/-

Bharat L Tanna

FCS No. 4106

C.P.No. 2419

Date: 04.07.2022

Place : Mumbai

UDIN :-F004106D000560167

Note: This report is to be read with our letter of even date which is annexed as an Annexure and forms an integral Annual Report part of this report.

ANNEXURE

To
The Members
Jupiter Life Line Hospitals Limited
1004, 10th Floor, 360 Degree Business Park,
Maharana Pratap Chowk, L.B.S. Marg,
Mulund (W), Mumbai - 400 080

1. Maintenance of secretarial records is the responsibility of the management of the Company. My responsibility is to express an opinion on these secretarial records based on audit.
2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on a random test basis to ensure that correct facts are reflected in secretarial records. I believe that the processes and practices, followed provide a reasonable basis for opinion.
3. I have not verified the correctness and appropriateness of financial records and books of accounts of the Company.
4. Where ever required, I have obtained the Management representation about the compliance of laws, rules and regulations and occurrence of events.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of the management. My examination was limited to the verification of procedures on a random test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For B L Tanna & Co.

Sd/-

Bharat L Tanna
FCS No. - 4106
C.P.No.- 2419
Date :04.07.2022
Place : Mumbai

UDIN :- F004106D000560167

Form AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries or associate companies or joint ventures as on 31/03/2022.

Part A Subsidiaries

(Information in respect of each subsidiary to be presented with amounts in Rs.)

Sl. No.	Particulars	Details
1	Name of the subsidiary	Jupiter Hospital Projects Private Limited
2	The date since when subsidiary was acquired	11/03/2020
3	Reporting period for the subsidiary concerned, if different from the holding company's reporting period.	NO
4	Reporting currency and Exchange rate as on the last date of the relevant Financial year in the case of foreign subsidiaries.	NA
5	Share capital	80,00.00
6	Reserves and surplus	(5,243.98)
7	Total assets	24,495.12
8	Total Liabilities	21,739.10
9	Investments	1.90
10	Turnover	7,611.09
11	Profit before taxation	(2,859.49)
12	Provision for taxation (Deferred Tax)	494.86
13	Profit after taxation	(3,354.35)
14	Proposed Dividend	NIL
15	Extent of shareholding (in percentage)	Equity Share: 76.00 % OCRPS: 100.00 %

Notes: The following information shall be furnished at the end of the statement:

- Names of subsidiaries which are yet to commence operations – NO
- Names of subsidiaries which have been liquidated or sold during the year - NO

For Jupiter Life Line Hospitals Limited.

Sd/-

Sd/-

Dr. Ajay Pratap Thakker
Director
Din: 00120887

Dr. Ankit Ajay Thakker
Director
02874715

Part B Associates and Joint Ventures

NA

ANNEXURE - 4

The Annual Report on CSR Activities Included in the Board's Report for Financial Year 2021-22 of Jupiter Life Line Hospitals Limited (Pursuant to Rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014) AS on 31/03/2022

1. Brief outline of Jupiter Life Line Hospitals Limited CSR Policy.

Pursuant to Section 135 of the Companies Act, 2013 Jupiter Life Line Hospitals Limited has constituted the Corporate Social Responsibility (CSR) Committee of the Board of Directors.

Jupiter Life Line Hospitals Limited vision is to help the poor and needy people in the society and reducing the inequality between rich and poor people within local areas of the Company. With this goal Jupiter Life Line Hospitals Limited along with Jupiter Foundation is promoting the healthcare facilities by reaching to the people who are in pain and suffering, having various issues of accessibility and affordability.

Jupiter Life Line Hospitals Limited has formed the CSR Committee, inter alia which includes the following functions:

- i) To formulate and recommend to the board, a Corporate Social Responsibility policy which shall indicate the activities to be undertaken by the company as specified in Schedule VII.
- ii) To recommend the amount of expenditure to be incurred on the activities.
- iii) To monitor the Corporate Social Responsibility policy of the company from time to time.

2. Composition of CSR Committee:

Sl. No.	Name of Director	Designation / Nature of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
1	Mr. Nitin Thakker	Director	4	3
2	Dr. Bhaskar Shah	Director	4	4
3	Mr. Rajesh Vora	Director	4	3
4	Dr. Jasmin Patel	Independent Director	4	4
5	Dr. Darshan Vora	Independent Director	4	4

3. Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company.

4. Provide the details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, if applicable (attach the report).

The Company does not meet the criteria in terms of Rule 8 (3) of Companies (Corporate Social Responsibility Policy) Rules, 2014 and hence impact assessment is not applicable. However, the CSR Committee reviews the progress of various CSR projects undertaken by the Company and its impacts in terms of beneficiaries covered and the outcome of the programs.

5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any:

The Company has incurred an excess amount of Rs. 1,10,17,520/- for the CSR spending done in FY 2020-2021 which is available for set off under the provisions of sub-rule (3) of rule 7 of the Companies (Corporate Social Responsibility Policy) Rules, 2014. During the financial year Rs. 46,79,380/- is set off from the amount available for Setoff of previous financial year.

6. Average net profit of the company as per section 135(5): Rs. 2339.69 Lakhs

		Rs. In Lakhs
a	Two percent of average net profit of the company as per section 135(5)	46.79
b	Surplus arising out of the CSR projects or programmes or activities of the previous financial years.	110.17
c	Amount required to be set off for the financial year, if any	46.79
d	Total CSR obligation for the financial year (7a+7b-7c)	46.79

8. (a) CSR amount spent or unspent for the financial year:

Total Amount Spent for the Financial Year. (Rs.)	Amount Unspent (in Rs.)				
	Total Amount transferred to Unspent CSR Account as per section 135(6).		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5).		
	Amount	Date of transfer	Name of the Fund	Amount	Date of transfer
Rs.1,16,30,380/-	-	NIL	NIL	-	NIL

(b) Details of CSR amount spent against ongoing projects for the financial year:

(1)	(2)	(3)	(4)	(5)		(6)	(7)	(8)	(9)	(10)	(11)	
Sl. No.	Name of the Project	Item from the list of activities in Schedule VII to the Act	Local area (Yes/No)	Location of the project		Project duration	Amount allocated for the project (in Rs. Lakhs)	Amount spent in the current financial Year (in Rs.)	Amount transferred to Unspent CSR Account for the project as per Section 135 (6) (in Rs.)	Mode of Implementation - Direct (Yes/No)	Mode of Implementation - Through Implementing Agency	
				State	District						Name	CSR Registration number
1.	COVID 19	FY 31-03-2021-1	YES	MH	THANE	36 MONTHS	46,79,380	NIL	NIL	DIRECT	NA	NA
	Total						46,79,380	NIL	NIL			

(C) Details of CSR amount spent against other than ongoing projects for the financial year:

(1)	(2)	(3)	(4)	(5)		(6)	(7)	(8)	
Sl. No.	Name of the Project	Item from the list of activities in Schedule VII to the Act	Local area (Yes/No)	Location of the project		Amount allocated for the project (in Rs. Lakhs)	Mode of Implementation - Direct (Yes/No)	Mode of Implementation - Through Implementing Agency	
				State	District			Name	CSR registration number
1.	JCI HEALTH-CARE	2021-2022 -	YES	MAHA-RASHTRA	THANE	69,51,000	NO	JUPITER FOUNDATION	CSR00010403
	Total					69,51,000			

(d) Amount spent in Administrative Overheads: NIL

(e) Amount spent on Impact Assessment, if applicable: NA

(f) Total amount spent for the Financial Year (8b+8c+8d+8e): Rs. 1,16,30,380/-

(g) Excess amount for set off, if any

Sl. No.	Particular	Amount (Rs.)
(I)	Two percent of average net profit of the company as per section 135(5)	46,79,380
(ii)	Total amount spent for the Financial Year	-
(iii)	Excess amount spent for the financial year [(ii)-(I)]	46,79,380
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	1,10,17,520
(v)	Amount available for set off in succeeding financial years [(iii)-(iv)]	63,38,140

9. (a) Details of Unspent CSR amount for the preceding three financial years:

Sl. No.	Preceding Financial Year	Amount transferred to Unspent CSR Account under section 135 (6) (in Rs.)	Amount spent in the reporting Financial Year (in Rs.).	Amount transferred to any fund specified under Schedule VII as per section 135(6), if any.			Amount remaining to be spent in succeeding financial years (in Rs. lakhs)
				Name of the Fund	Amount (in Rs.).	Date of Transfer.	
1.	2018-19	-	-	-	-	-	75.80
2.	2019-20	-	-	-	-	-	58.94
	Total	-	-	-	-	-	134.74

(b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s): NIL

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
Sl. No.	Project ID	Name of the Project	Financial Year in which the project was commenced	Project Duration	Total amount allocated for the project (in Rs.)	Amount spent on the project in the reporting Financial Year (in Rs.)	Cumulative amount spent at the end of reporting Financial Year (in Rs.)	Status of the project - Completed / Ongoing.
1.								
	Total							

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year: NO

(asset-wise details).

(a) Date of creation or acquisition of the capital asset(s).

(b) Amount of CSR spent for creation or acquisition of capital asset.

(c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc.

(d) Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset).

11. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5). – NO

Sd/-

Sd/-

Dr. Ankit Ajay Thakker
Executive Director & CEO
02874715

Mr. Nitin Thakker
Chairman CSR Committee
00134554

Independent Auditor's Report**B.R. Kotecha & Co.
BAKULESH KOTECHEA
CHARTERED ACCOUNTANTS**

3104, Tower 4, Valentine
Runwal Anthurium
LBS Road, Op. Veena Nagar
Mulund (W), Mumbai 400 080
B.Com, FCA
Mobile: 9820012065

To,
The Members of Jupiter Lifeline Hospitals Limited

Report on the Standalone Financial Statements

We have audited the accompanying standalone financial statements of Jupiter Lifeline Hospitals Limited, which comprise the Balance sheet as at March 31, 2022 and the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Cash Flows and the Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the standalone financial statements").

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS"), and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and its Profit, total comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(I) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A", a statement on the matters specified in the paragraph 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143 (3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - (c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Statement of Cash Flows and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account.

- (d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act .
- (e) On the basis of the written representations received from the directors as on 31 March 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2022 from being appointed as a director in terms of Section 164 (2) of the Act;
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in “Annexure B”; and
- (g) With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- The Company has disclosed the impact, if any of pending litigations on its financial position in its financial statements;
 - The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts; and
 - There are no amounts which are required to be transferred to the Investor Education and Protection Fund by the Company.

For B. R. Kotecha & Co.

Chartered Accountants

Firm’s registration number: 105283W

Sd/-

Bakulesh Kotecha

Proprietor

Membership number: 036309

Place: Mumbai

Date : 04/07/2022

UDIN : 22036309AMJQZB9972

Annexure-A to the Auditors’ Report

The “Annexure-A” referred to in our Independent Auditor’s report to the members of the Company on Financial Statements for the year ended on March 31, 2022 We report that:

- (I) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
- (B) The Company has maintained proper records showing full particulars of Intangible Assets.
- (b) The major Property, Plant and Equipment of the company have been physically verified by the management at reasonable intervals during the year and no material discrepancies were noticed on such verification.
- (c) According to the information and explanation given to us, the title deeds of the immovable properties are held in the name of the company.
- (d) The Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year
- (e) According to the information and explanation given to us, no proceedings have been initiated or are pending against the company for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder during the year.
- (ii) (a) The management has conducted physical verification of inventory at reasonable intervals during the year, in our opinion, the coverage and procedure of such verification by the management is appropriate. As informed to us, any discrepancies of 10% or more in the aggregate for each class of inventory were not noticed on such verification.
- (b) The company has been sanctioned working capital limits in excess of five crore rupees (at any point of time during the year), in aggregate, from banks or financial institutions on the basis of security of current assets; quarterly returns or statements filed by the company with such banks or financial institutions are in agreement with the books of account of the Company;
- (iii) During the year the company has made investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties:
- (a) during the year the company has provided loans or provided advances in the nature of loans, or stood guarantee, or provided security to any other entity :

To whom	The aggregate amount during the year	Balance outstanding at the balance sheet date
Parties other than subsidiaries, joint ventures and associates	-	-
Subsidiaries, joint ventures and associates	28,00,00,000	23,00,00,000

- (b) According to the information and explanation given to us, the investments made, guarantees provided, security given and the terms and conditions of the grant of all loans and advances in the nature of loans and guarantees provided are not prejudicial to the company's interest;
- (c) schedule of repayment of the principal amount and the payment of the interest have not been stipulated and hence we are unable to comment as to whether receipt of the principal amount and the interest is regular;
- (d) According to the information and explanation given to us, no amount is overdue in these respect;
- (e) According to the information and explanation given to us, in respect of any loan or advance in the nature of loan granted which has fallen due during the year, none has been renewed or extended or fresh loans granted to settle the overdues of existing loans given to the same parties;
- (f) The company has granted loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment, required details in respect thereof are as below:

During the year, the company has given an amount of Rs.28 crores to its subsidiary Jupiter Hospital Projects Private Limited. Of the said amount, Rs. 23 crores is outstanding as on 31/03/2022. As per the management, this amount given to the subsidiary is for meeting their working capital requirements and furtherance of business. No interest is being received by the company for this amount given and the same is not to be considered as given in the nature of loan.

- (iv) According to the information and explanation given to us, the company has complied with requirements of section 185 and 186 in respect of loans, investments, guarantees or security made by it during the year under audit;

The company has provided following mentioned loans within the meaning of section 185 & 186 of the Companies Act, 2013

During the year the company has given advance of Rs.80 lakhs to M/s. Entisi (a partnership firm in which director is partner or relative is a partner) . As per management the said advance has been paid for purchase of goods and is not in the nature of loans.

- (v) The Company has not accepted any deposits or amounts which are deemed to be deposits under the directives of the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Companies Act, 2013 and the rules framed thereunder, where applicable. Accordingly, the provisions of clause 3(v) of the Order are not applicable.
- (vi) Maintenance of Cost Records are prescribed to be maintained u/s 148(1) of Companies Act, 2013. Rules for same have been notified vide Companies (Cost Records and Audit) Rules 2014 on 30th June 2014. Company being engaged in services of running hospital which is listed in sub clause (x) Of clause C of rule 3 of said rules and its turnover has exceeded prescribed limits. Company is maintaining proper books of accounts. Cost records are integral part of books of accounts. However, we are unable to give opinion on adequacy of requirements of Cost records as mentioned in CRA I of above referred rules.
- (vii)(a) The Company is regular in depositing undisputed statutory dues including Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues, as applicable, with the appropriate authorities. Further, no undisputed amounts payable in respect thereof were outstanding at the year-end for a period of more than six months from the date they became payable.
- (b) There are no dues in respect of Goods and Services Tax, provident fund, employees' state insurance, income-tax, service tax, duty of customs, duty of excise, cess and any other statutory dues except under the value added tax act that have not been deposited with the appropriate authorities on account of any dispute.

Order under the MVAT act has been passed raising the demands as follows:

F.Y.2013-14 Rs.640203/-

F.Y.2014-15 Rs.256626/-

F.Y.2015-16 Rs.471253/-

F.Y.2017-18 Rs.389142/-

This demand has not yet been paid as the company has decided to opt in for the Maharashtra Amnesty Scheme, 2022 and discharge the demand through the said scheme.

- (viii) According to the information and explanation given to us, company has no transactions, not recorded in the books of account have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961)
- (ix) (a) In our opinion, the company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender during the year;
- (b) Company is not declared wilful defaulter by any bank or financial institution or other lender;
- (c) According to the information and explanation given to us, term loans were applied for the purpose for which the loans were obtained;
- (d) According to the information and explanation given to us, funds raised on short term basis have not been utilised for long term purposes;
- (e) According to the information and explanation given to us, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures;
- (f) According to the information and explanation given to us, the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies;
- x) (a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year;
- (b) The company has made private placement of shares under review and the requirement of section 42 and section 62 of the Companies Act, 2013 have been complied with and according to information and explanations given to us, the amount raised have been used for the purposes for which the funds were raised.
- (xi) (a) According to the information and explanation given to us, any fraud by the company or any fraud on the company has not been noticed or reported during the year;
- (b) According to the information and explanation given to us, no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government;
- (c) According to the information and explanation given to us, no whistle-blower complaints, received during the year by the company;
- (xii) Company is not a Nidhi company, accordingly provisions of the Clause 3(xii) of the Order is not applicable to the company.
- (xiii) According to the information and explanations given to us, we are of the opinion that all transactions with related parties are in compliance with Section 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc., as required by the Accounting Standards and the Companies Act, 2013.
- (xiv) (a) According to the information and explanations given to us, the company has an internal audit system commensurate with the size and nature of its business;
- (b) We have considered the reports of the Internal Auditors for the period under audit;
- (xv) According to the information and explanations given to us, we are of the opinion that the company has not entered into any non-cash transactions with directors or persons connected with him and accordingly, the provisions of clause 3(xv) of the Order is not applicable.
- (xvi) According to the information and explanations given to us, we are of the opinion that the company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 and the company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India, accordingly the provisions of clause 3(xvi) of the Order are not applicable;

- (xvii) According to the information and explanations given to us and based on the audit procedures conducted we are of opinion that the company has not incurred any cash losses in the financial year and the immediately preceding financial year
- (xviii) There has been no resignation of the statutory auditors during the year and accordingly, the provisions of clause 3(xviii) of the Order is not applicable;
- (xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that company is incapable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.
- (xx) (a) There is no unspent amount towards Corporate Social Responsibility (CSR) on other than on-going projects requiring a transfer to a Fund specified in Schedule VII to the Companies Act in compliance with second proviso to sub-section (5) of Section 135 of the said Act. Accordingly, reporting under clause 3(xx)(a) of the Order is not applicable for the year.
(b) There is no amount remaining unspent under sub-section (5) of section 135 of the Companies Act, pursuant to any on-going project. Accordingly, reporting under clause 3(xx)(b) of the Order is not applicable for the year.
- (xxi) There are no any qualifications or adverse remarks given by the respective auditors in the Companies (Auditor's Report) Order (CARO) reports, hence this clause is not applicable to the company.

Annexure-B to the Auditors' Report

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of Jupiter Lifeline Hospitals Limited ("the Company") as of March 31, 2022 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2022 based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **B. R. Kotecha & Co.**

Chartered Accountants

Firm's registration number: 105283W

Sd/-

Bakulesh Kotecha

Proprietor

Membership number: 036309

Date: 04/07/2022

UDIN: 22036309AMJQZB9972

Standalone Balance Sheet for the year ended March 31, 2022
Rs. In Lakhs

Sr. No	Particulars	Note No.	As at March 31 2022	As at March 31 2021
I.	ASSETS:			
1.	Non-Current Assets:			
	(a) I Property, plant and equipment	3	46,390.17	42,603.32
	(b) II Capital work-in-progress	3	1,385.69	1,333.45
	(c) III Goodwill		-	-
	(d) IV Other intangible assets	3	68.18	38.39
	(e) Financial assets:			
	(i) Other financial assets	4	613.56	289.59
	(ii) Investments	5	6,803.16	5,803.16
	(iii) Trade receivables		-	-
	(f) Deferred tax asset [net]		-	-
	(g) Other non-current assets	7	2,571.72	543.70
			57,832.48	50,611.61
2.	Current Assets:			
	(a) Inventories	8	1,329.49	1,152.71
	(b) Financial assets:			
	(i) Investments	9	283.08	730.75
	(ii) Trade receivables	10	2,765.02	2,043.00
	(iii) Cash and cash equivalents	11	10,215.89	1,907.52
	(iv) Loans	12	53.55	69.32
	(c) Other current assets	13	2,995.08	5,002.52
			17,642.10	10,905.81
	Total Assets (1+2) :		75,474.59	61,517.42
II.	EQUITY AND LIABILITIES:			
1. Equity:				
	Equity share capital	14	5,086.66	5,086.66
	Instruments entirely equity in nature	14	178.80	-
	Other equity	15	27,621.86	20,247.04
			32,887.31	25,333.70
	Non-current liabilities:			
	(a) Financial liabilities:			
	(i) Borrowings	16	29,787.63	25,815.10
	(ii) Other financial liabilities		-	-
	(b) Provisions		-	-
	(c) Deferred tax liabilities [net]	6	2,469.69	2,256.33
	(d) Other non current liabilities		-	-
			32,257.32	28,071.43
	Current liabilities:			
	(a) Financial Liabilities:			
	(i) Borrowings	17	2,426.30	351.86
	(ii) Trade payables:			
	Due to Micro, Small and Medium Enterprises		-	-
	Due to other than Micro, Small and Medium Enterprises	18	5,362.04	4,970.45
	(iii) Other financial liabilities		-	-
	(b) Other current liabilities	19	992.93	849.43
	(c) Provisions	20	1,383.83	1,640.05
	(d) Current tax liabilities [net]	21	164.86	300.50
			10,329.96	8,112.29
	Total Equity & Liabilities (1+2+3) :		75,474.59	61,517.42
	Significant Accounting Policies	2		
	Notes to the Financial Statements	1 to 35		

As per our report of even date
For B. R. Kotecha & Co.
Chartered Accountants
Firm's Registration No.105283W

For and on behalf of the Board of Directors of
Jupiter Lifeline Hospitals Limited

Sd/-

B.R.Kotecha
(Proprietor)
Membership No.036309
04/07/2022
Mumbai
UDIN : 22036309AMJQZB9972

Sd/-

Dr. Ajay P Thakker
Managing Director

Sd/-
Chief Financial Officer

Sd/-

Dr. Navinchandra Davda
Director

Sd/-
Company Secretary

Standalone Statement of Profit and Loss for the year ended March 31, 2022
Rs. In Lakhs

	Particulars		As at March 31	
			2022	2021
I	REVENUE:			
	(a) Revenue from operations	22	65,727.85	46,109.55
	(b) Other income	23	375.45	402.88
	Total Income		66,103.30	46,512.43
II	EXPENSES:			
	(a) Cost of materials consumed		-	-
	(b) Purchases of stock-in-trade	24	12,841.76	9,185.84
	(c) Changes in inventories of finished goods, work-in-Progress and stock-in-trade	25	(177.43)	243.08
	(d) Employee benefits expense	26	11,690.00	10,039.96
	(e) Finance costs	27	2,923.37	2,817.00
	(f) Depreciation and amortisation expenses	28	2,765.87	2,738.28
	(g) Other expenses	29	25,488.47	19,733.35
	Total Expenses		55,532.05	44,757.50
III	Profit or Loss before exceptional items and tax (I-II)		10,571.25	1,754.93
	Exceptional items		-	-
IV	Profit or Loss before tax		10,571.25	1,754.93
	Less: Tax expense:	30	2,104.14	95.62
V	Profit or Loss for the year (III-IV)		8,467.11	1,659.31
VI	Other Comprehensive Income [OCI]		-	-
VII	Total Other Comprehensive Income for the year (VI)		-	-
VIII	Total Comprehensive Income for the year (V+VII)		8,467.11	1,659.31
IX	Basic Earnings per equity share [EPS]	31	16.65	3.26
X	Diluted Earnings per equity share [EPS]	31	16.65	3.26
	Significant Accounting Policies	2		
	Notes to the Financial Statements	1 to 35		

As per our report of even date
For B. R. Kotecha & Co.
Chartered Accountants
Firm's Registration No.105283W

Sd/-

B.R.Kotecha
(Proprietor)
Membership No.036309
04/07/2022
Mumbai
UDIN : 22036309AMJQZB9972

Sd/-
Dr. Ajay P Thakker
Managing Director

Sd/-
Chief Financial Officer

For and on behalf of the Board of Directors of
Jupiter Lifeline Hospitals Limited

Sd/-
Dr. Navinchandra Davda
Director

Sd/-
Company Secretary

Standalone Cash Flow Statement for the period ended 31st March 2022
Rs. In Lakhs

	Particulars	As at March 31 2022	As at March 31 2021
A.	CASH FLOW FROM OPERATING ACTIVITIES:		
	Profit Before Tax	10,571.25	1,754.93
	Adjustment for:		
	Share in profits of Jupiter Pharmacy	(195.06)	(191.30)
	Share in loss of Partnership Firms	103.10	156.27
	Depreciation	2,765.87	2,738.28
	Dividend received	(0.75)	-
	Profit from Sale of Asset	(31.42)	-
	Interest Income	(150.02)	(23.33)
	Finance Cost	2,923.37	2,817.00
	Other Income	(20.62)	(55.49)
		5,394.47	5,441.42
	Operating profit before working capital change	15,965.72	7,196.35
	Adjusted for		
	Trade and other receivable	(722.02)	2,357.40
	Inventories	(176.78)	244.14
	Other Current assets	915.14	2,194.02
	Current Liabilities and provision	(885.23)	302.41
		(868.89)	5,097.97
	Cash Generated from operations	15,096.83	12,294.32
	Taxes Paid (net of refunds)	(1,262.33)	(1,172.52)
	Income Tax Paid	400.01	193.10
	Net Cash from operating activities	14,234.50	11,314.89
B	Cash flow from Investing Activities		
	Purchase of Fixed Assets	(6,634.75)	(2,207.45)
	Investments in Corporates and Partnership Firms	(460.37)	(5,693.17)
	Interest Income	150.02	23.33
	Dividend Income	0.75	-
	Other Income	52.04	55.49
	Net Cash used in Investing Activities	(6,892.31)	(7,821.79)
C	Cash Flow from Financing Activities		
	Proceed from Call money received	178.80	-
	Inflow from Non Current Financial and Other Assets	(2,351.99)	-
	Inflow from Short Term Loans & Advances	15.77	562.50
	Proceed from Long Term Borrowings	4,274.47	2,670.80
	Repayment Long Term Borrowings	(1,206.25)	(859.41)
	Proceed from Short Term Borrowing	2,978.76	(1,899.64)
	Proposed Dividend & Dividend distribution Tax	-	-
	Interest Paid	(2,923.37)	(2,817.00)
	Net Cash from Financing Activities	966.18	(2,342.74)
	Net Increase in Cash and Cash equivalent	8,308.37	1,150.35
	Opening Balance of Cash and Cash equivalent	1,846.21	695.86
	Add : Credit Card Receivables & Others	61.31	-
	Closing Balance of Cash and Cash equivalent	10,215.89	1,846.21
	Net Increase in Cash and Cash equivalent	8,308.37	1,150.35

Notes:

- 1) The cash flow statement has been prepared in accordance with the requirements of Ind AS 7 - issued in terms of the Companies Act, 2013.
- 2) The figures in brackets indicate outflows of cash and cash equivalents.
- 3) Previous year's figures are re-grouped, re-arranged and reclassified wherever necessary.

As per our report of even date
For B. R. Kotecha & Co.
Chartered Accountants
Firm's Registration No.105283W

For and on behalf of the Board of Directors of
Jupiter Lifeline Hospitals Limited

Sd/-

B.R.Kotecha
(Proprietor)
Membership No.036309
04/07/2022
Mumbai
UDIN : 22036309AMJQZB9972

Sd/-

Dr. Ajay P Thakker
Managing Director

Sd/-
Chief Financial Officer

Sd/-

Dr. Navinchandra Davda
Director

Sd/-
Company Secretary

Standalone Statement of Change in Equity for the year ended March 31, 2022

1	Equity Share Capital:								
	Equity Shares of Rs.10/- each, Issued, Subscribed and Fully Paid-up:								
	Balance at the beginning of the current reporting period Changes in Equity Share Capital due to prior period errors Restated balance at the beginning of the current reporting period Changes in equity share capital during the current year Balance at the end of the current reporting period	March 31 2022		March 31 2021					
		No. of Shares	Rs. in Lakhs	No. of Shares	Rs. in Lakhs				
		50,866,551	5,086.66	50,866,551	5,086.66				
		-	-	-	-				
-		-	-	-					
2	Instruments entirely equity in nature : (Any other instrument) Share warrant @ Rs.63.27 x 5%		March 31 2022		March 31 2021				
			No.	Rs. in Lakhs	No.	Rs. in Lakhs			
			-	-	-	-			
	Balance at the beginning of the current reporting period Changes in instrument due to prior period errors Restated balance at the beginning of the current reporting period Changes in instrument during the period Balance at the end of the current reporting period		-	-	-	-			
			-	-	-	-			
			-	-	-	-			
			5,651,839	178.80	-	-			
			5,651,839	178.80	-	-			
	3	Other Equity: Particulars		Reserves and Surplus				Money received against share warrants	Total
				Capital Reserve	Securities Premium	General Reserve	Retained Earnings		
		-	1,063.87	1,957.55	15,566.32	-	18,587.73		
Balance at the beginning of the current reporting period		-	-	-	-	-	-		
Changes in accounting policy or prior period errors		-	-	-	-	-	-		
Restated balance at the beginning of the current reporting period		-	-	-	-	-	-		
Total Comprehensive Income for the current year		-	-	165.93	1,659.31	-	1,825.24		
Less: Dividend		-	-	-	-	-	-		
Any other change (to be specified)		-	-	-	(165.93)	-	(165.93)		
Balance at the end of the current reporting period		-	-	-	-	-	-		
As at March 31, 2021		-	1,063.87	2,123.48	17,059.70	-	20,247.04		
Balance at the beginning of the current reporting period		-	1,063.87	2,123.48	17,059.70	-	20,247.04		
Changes in accounting policy or prior period errors		-	-	-	-	-	-		
Restated balance at the beginning of the current reporting period		-	-	-	-	-	-		
Total Comprehensive Income for the current year		-	-	846.71	8,467.11	-	9,313.82		
Less: Dividend		-	-	-	-	-	-		
Any other change (to be specified)		-	-	-	(1,939.01)	-	(1,939.01)		
Balance at the end of the current reporting period		-	-	-	-	-	-		
As at March 31, 2022		-	1,063.87	2,970.19	23,587.80	-	27,621.86		

Notes on standalone Financial Statement for the year ended 31st March 2022
Note: 3 - Property, plant and equipment:

Particulars	Gross Block					Depreciation and Impairment:					Rs. in Lakhs	
	As at March 31, 2020	Additions	Disposals	As at March 31, 2021	As at March 31, 2022	Disposals	Additions	As at March 31, 2021	Additions	Disposals	As at March 31, 2022	As at March 31, 2021
Freehold Land	3,599.00	-	-	3,599.00	7,467.88	-	3,868.88	-	-	-	7,467.88	3,599.00
Leasehold Land	-	-	-	-	-	-	-	-	-	-	-	-
Buildings	21,394.15	482.15	-	21,876.30	22,150.83	-	274.53	2,321.75	337.62	-	2,987.88	19,226.04
Plant & Equipment	6,322.30	240.85	-	6,563.15	6,637.89	-	74.74	2,201.52	445.49	-	3,105.58	3,916.14
Furniture & Fixtures	5,542.76	111.65	-	5,654.41	6,098.44	-	444.03	2,888.75	381.43	-	3,671.48	2,384.23
Vehicles	269.07	6.32	-	275.39	205.69	79.18	9.48	121.59	27.54	41.60	131.70	126.26
Office Equipment	250.43	23.99	-	274.42	316.59	-	42.17	176.20	22.75	-	227.66	75.47
Medical Equipments - 40% IT	5,848.42	120.52	-	5,968.94	5,975.57	6.63	6.63	1,889.14	430.69	-	2,728.28	3,649.11
Medical Equipments - Others	13,663.93	856.52	-	14,520.45	16,010.81	59.88	1,550.24	3,995.67	1,034.87	10.37	6,018.65	9,489.91
Wind Power Generation	-	-	-	-	284.78	-	284.78	-	-	-	29.90	-
Computer	543.57	76.25	-	619.82	686.98	-	67.16	430.20	52.46	-	544.16	137.16
Total	57,433.63	1,918.25	-	59,351.88	65,835.46	139.06	6,622.64	14,024.82	2,723.74	51.97	19,445.29	42,603.32

Notes:3 - Capital Work in Progress
CWIP Ageing Schedule

CWIP	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in Progress	885.59	0.80	499.30	-	1,385.69
Projects temporarily suspended	-	-	-	-	-
Total	885.59	0.80	499.30	-	1,385.69

Note: 3 - Goodwill and Other intangible assets:

Particulars	Gross Block					Depreciation and Impairment:					Rs. in Lakhs	
	As at March 31, 2020	Additions	Disposals	As at March 31, 2021	As at March 31, 2022	Disposals	Additions	As at March 31, 2021	Additions	Disposals	As at March 31, 2022	As at March 31, 2021
Software/Others	117.49	5.88	-	123.37	170.33	-	46.96	70.44	14.53	-	102.15	38.39
Total	117.49	5.88	-	123.37	170.33	-	46.96	70.44	14.53	-	102.15	38.39

Notes on standalone Financial Statement for the year ended 31st March 2022
Note: 4 - Other financial assets:
Rs. In Lakhs

Particulars	As at 31 st March	
	2022	2021
[Unsecured, Considered Good unless otherwise stated]		
Security Deposits	335.75	289.59
Fixed Deposits	277.82	-
Total	613.56	289.59

Note: 5 - Investments

Particulars	As at 31 st March	
	2022	2021
[Unsecured, Considered Good unless otherwise stated]		
Investments shall be classified as		
Jupiter Hospital Projects Private Limited		
Investments in Equity Shares (3,80,00,000 Equity shares of Rs.10 each)	3,800.00	3,800.00
Investments in Preference Shares (3,00,00,000 OCRPS of Rs.10 each)	3,000.00	2,000.00
Investments in partnership firms	3.16	3.16
Total	6,803.16	5,803.16

Investment in Partnership Firms

Name of Partnership Firm*	Name of Partners	Partner's Share
1. Jupiter Pharmacy	Jupiter Lifeline Hospitals Limited	95%
	Mr.Rajendra Thakker	5%
2. Jupiter Gait Lab	Jupiter Lifeline Hospitals Limited	51%
	Dr.Taral Nagda	12%
	Dr.Punita Nagda	37%
3. Eflow Solutions	Jupiter Lifeline Hospitals Limited	75%
	Mr.Chandrashekar Reddy	20%
	Dr. Ankit Thakker	5%
4. Katyayini Hospitality	Jupiter Lifeline Hospitals Limited	95%
	Mr.Anshul Sethi	5%

Note: 6 - Deferred tax [net]:

A. Break up of deferred tax liabilities and assets into major components of the respective balances are as under:

Particulars	As at 31 st March	
	2022	2021
Deferred Tax Liabilities:		
Impact for the previous year	2,256.33	1,967.61
Impact for the current year	213.36	288.72
Net Deferred Tax (Liabilities)	2,469.69	2,256.33

Note: 7 - Other non-current assets:

Particulars	As at 31 st March	
	2022	2021
[Unsecured, Considered Good unless otherwise stated]		
Capital Advances	271.72	42.46
Advances with Subsidiary JHPPL	2,300.00	501.24
Total	2,571.72	543.70

Notes on standalone Financial Statement for the year ended 31st March 2022
Note: 8 - Inventories:
Rs. In Lakhs

Particulars	As at 31 st March	
	2022	2021
Classification of Inventories:		
Medical, drug and surgical consumables	1,326.41	1,149.01
Hotel consumables	3.07	3.70
Total	1,329.49	1,152.71

Note: 9 - Investments:

Particulars	As at 31 st March	
	2022	2021
A. (i) Aggregate amount of quoted investments and aggregate value thereof:		
New India Co-op Bank Ltd (50,000 Equity Shares of Rs. 10/- Each)	5.00	5.00
The TJSB Ltd.(9,999 Equity Shares of Rs. 50/- Each)	5.00	5.00
Jupiter Eco Energy Pvt. Ltd. (2600 Equity Shares of Rs. 10/- Each)	-	0.26
B. Investment in Partnership firms	273.08	720.49
Total	283.08	730.75

Note: 10 - Trade receivables:

Particulars	As at 31 st March	
	2022	2021
Unsecured - Considered good	2,765.02	2,043.00
Unsecured - Credit impaired	-	-
	2,765.02	2,043.00
Less: Allowances for credit losses	-	-
Total	2,765.02	2,043.00

Note: 11 - Cash and cash equivalents:

Particulars	As at 31 st March	
	2022	2021
Balances with banks		
Current Accounts	2,241.65	1,285.83
Fixed Deposits with Banks	7,807.66	414.46
Cash on hand	100.46	146.60
Balance receivable from Credit Cards	66.12	60.63
Total	10,215.89	1,907.52

Note: 12 - Loans:

Particulars	As at 31 st March	
	2022	2021
i Loans shall be classified as:-		
a Loans to related Parties	-	-
b Other Loans	53.55	69.32
ii Loans receivables	-	-
iii Allowance for bad and doubtful loans	-	-
iv Loans due by directors or other Officers	-	-
Total	53.55	69.32

Notes on standalone Financial Statement for the year ended 31st March 2022
Note: 13 - Other current assets:
Rs. In Lakhs

Particulars	As at 31 st March	
	2022	2021
[Unsecured, Considered Good unless otherwise stated]		
Advances to suppliers	254.60	100.49
Prepaid Expenses	221.87	400.20
MAT Credit Entitlement	1,597.80	2,690.10
Balances with Statutory Authorities	903.18	1,804.22
Others	17.63	7.51
Total	2,995.08	5,002.52

Note: 14 - Equity share capital:

Particulars	As at 31 st March	
	2022	2021
Authorised: 60,000,000 (60,000,000) Equity shares of Rs.10/- each	6,000.00	6,000.00
	6,000.00	6,000.00
Issued, Subscribed and fully Paid-up: 50,866,551 (50,866,551) Equity Shares of Rs.10/- each fully Paid	5,086.66	5,086.66
	5,086.66	5,086.66
Instruments entirely equity in nature Share warrant no 5651839 @ Rs.63.27 x 5%	178.80	-
Total	178.80	-

[30,00,000 convertible warrants have been allotted to Dr. Ajay P. Thakker & 26,51,839 convertible warrants have been allotted to Ankit Thakker . The warrants are allotted @ 63.27 as per valuation report dated 06 September 2021. As of 31-Mar-2022 , 5% payment has been received towards the allotment of the warrants. Balance 95% amount shall be payable by the warrant holders on the exercise of the warrant]

Particulars	As at 31 st March	
	2022	2021
A. The reconciliation in number of equity share is as under:		
Number of shares at the beginning of the year	5,086.66	5,086.66
Add: Shares issued during the year	-	-
Number of shares at the end of the year	5,086.66	5,086.66
Total	5,086.66	5,086.66

B. The Company has equity shares which ranks pari passu and carry equal rights with respect to voting and dividend.

Particulars	As at 31 st March			
	2022		2021	
C. Details of Shareholder holding more than 5% of shares:	No. of Shares	%	No. of Shares	%
a. Equity Shares:				
Wisdom Wellness Private Limited	9,800,000	19.27	9,800,000	19.27
Ajay P Thakker	8,123,329	15.97	8,123,329	15.97
Western Medical Solutions LLP	5,703,797	11.21	5,703,797	11.21
Nitin Manilal Thakker	3,220,000	6.33	3,220,000	6.33

D The company during the preceeding five years has not:
Allotted any shares other than cash or Allotted any shares by way of bonus shares or bought back any shares

Notes on standalone Financial Statement for the year ended 31st March 2022
Disclosure of Shareholding of Promoters:
(Rs. In Lakhs)

Shares held by promoters at the end of the year				
S. No	Promoter name	No. of Shares**	% of total shares	% Change during the year***
1	Dr. Ajay P Thakker	8,123,329	15.97%	NIL

*Promoter here means promoter as defined in the Companies Act, 2013.

** Details shall be given separately for each class of shares

*** percentage change shall be computed with respect to the number at the beginning of the year or if issued during the year for the first time then with respect to the date of issue.]

Note: 15 - Other equity:

Particulars	As at 31 st March	
	2022	2021
General Reserve:		
Balance as per last Balance Sheet	2,123.48	1,957.55
Addition during the year	846.71	165.93
Balance at the end of the year	2,970.19	2,123.48
Securities Premium:		
Balance as per last Balance Sheet	1,063.87	1,063.87
Add: Addition pursuant to issue of shares (net of redemption)	-	-
Balance as at the end of the year	1,063.87	1,063.87
Retained Earnings:		
Balance as per last Balance Sheet	17,059.70	15,566.32
Add: Profit for the year	8,467.11	1,659.31
Less: Transfer to General Reserve	(846.71)	(165.93)
Less: MAT credit entitlement	(1,092.30)	-
Add: Other Comprehensive income for the year	-	-
Balance as at the end of the year	23,587.80	17,059.70
Total	27,621.86	20,247.04

Note: 16 - Borrowings:

Particulars	As at 31 st March	
	2022	2021
Secured Term Loans:		
i From Bank	29,787.63	25,815.10
ii From other parties	-	-
Total	29,787.63	25,815.10

Terms & Conditions for long term secured borrowings from Banks

Nature of Security	Name of Bank & Sanctioned & Disbursed Amount	
1 The facilities are secured by pari-passu charge by way of mortgage of immovable property at Thane & Pune.	ICICI Bank Ltd.	Rs. 167 Crores
2 Hypothecation of Movable Fixed Assets located at Thane & Pune.	Axis Bank Ltd.	Rs. 99.83 Crores
3 Current Assets included receivables located at Thane & Pune. All term Loans are repayable monthly as per schedule of repayment in 10 Years. Interest @ 7.75 % P.A.	ICICI Bank Ltd.	Rs. 35 Crores

Notes on standalone Financial Statement for the year ended 31st March 2022
Note: 17 - Borrowings:
(Rs. In Lakhs)

Particulars	As at 31 st March	
	2022	2021
Secured cash credit and other loan from bank	2,124.37	(854.39)
Current Maturities of Long Term Loan	301.93	1,206.25
Total	2,426.30	351.86

The Company has availed secured working capital facilities from ICICI Bank Ltd. and Axis Bank Ltd. of Rs. 18 Cr and Rs. 17 Cr respectively, with paripassu security of Term Loan available.

Note: 18 -Trade Payables:

Particulars	As at 31 st March	
	2022	2021
Due to Micro and Small Enterprises		
Due to other than Micro and Small Enterprises	5,362.04	4,970.45
Total	5,362.04	4,970.45

Note: 19 - Other current liabilities:

Particulars	As at 31 st March	
	2022	2021
Other Refundable Deposit	7.17	5.48
Advance received from Patient	580.55	446.63
Security deposit	405.10	269.06
Interest accrued and due on borrowings	0.12	128.26
Total	992.93	849.43

Note: 20 - Provisions:

Particulars	As at 31 st March	
	2022	2021
Provision for Income tax	-	557.62
Provision for Expenses	1,022.21	841.92
Statutory Dues	361.62	240.51
Total	1,383.83	1,640.05

Note: 21 - Current tax liabilities [net]:

Particulars	As at 31 st March	
	2022	2021
Provision for taxation	164.86	300.50
Total	164.86	300.50

Notes on standalone Financial Statement for the year ended 31st March 2022
Note: 22 - Revenue from Operations:

(Rs. In Lakhs)

Particulars	As at 31 st March	
	2022	2021
Income from Hospital & Operational Services	65,727.85	46,109.55
Total	65,727.85	46,109.55

Note: 23 - Other Income:

Particulars	As at 31 st March	
	2022	2021
Other Income	375.45	402.88
Total	375.45	402.88

Note: 24 - Purchases of stock-in-Trade:

Particulars	As at 31 st March	
	2022	2021
Purchases of stock-in-trade	12,841.76	9,185.84
Total	12,841.76	9,185.84

Note: 25 - Changes in inventories:

Particulars	As at 31 st March	
	2022	2021
Stock at commencement:	1,148.98	1,392.06
Less: Stock at close	1,326.41	1,148.98
Total	(177.43)	243.08

Note: 26 - Employee Benefits Expense:

Particulars	As at 31 st March	
	2022	2021
Salaries and wages	9,849.10	8,669.05
Contribution to provident and other funds	509.39	453.79
Staff welfare expenses	1,160.20	783.05
Gratuity Premium	132.94	90.78
Other Expenses	38.37	43.29
Total	11,690.00	10,039.96

Note: 27 - Finance cost:

Particulars	As at 31 st March	
	2022	2021
Interest expense	2,222.93	2,400.20
Bank commission and charges	700.44	416.80
Total	2,923.37	2,817.00

Notes on standalone Financial Statement for the year ended 31st March 2022
Note: 28 - Depreciation and amortisation expenses:
(Rs. In Lakhs)

Particulars	As at 31 st March	
	2022	2021
Depreciation	2,748.70	2,723.75
Amortisation Expenses	17.17	14.53
Total	2,765.87	2,738.28

Note: 29 - Other Expenses:

Particulars	As at 31 st March	
	2022	2021
Rent, Rates & Taxes	628.15	515.02
Repairs & Maintenance	489.74	308.27
Direct Overheads	1,146.42	1,217.96
Food Expenses	361.55	226.87
Electricity Charges	1,376.91	1,420.88
General Maintenance Contract Charges	894.99	608.27
Consumables	450.44	325.37
Printing & stationery	247.53	187.39
Business Promotion	329.34	64.70
Ambulance Manpower	112.55	97.81
Catering Manpower Services	232.25	-
Housekeeping Charges	1,944.41	1,527.86
Hvac & Electrical Manpower	185.01	155.43
Manpower Hiring Charges	18.06	-
Stp Manpower	10.22	10.19
Patient Food Expenses	634.47	481.17
Security Charges	993.92	874.65
Professional Fees	14,306.45	10,519.65
Balance W/off	80.57	264.88
Other Expenses less than 1% of Revenue	1,034.56	913.99
	25,477.54	19,720.36
Payment to the Statutory Auditors [excluding Taxes]:		
As Auditor	10.93	12.99
For Other Services	-	-
Total	25,488.47	19,733.35

Note: 30- Tax Expenses:
A. The major components of income tax expense for the year ended March 31, 2021 and March 31, 2022 are:

Particulars	As at 31 st March	
	2022	2021
Profit or loss section:		
Current income tax:		
Current income tax charge	2,923.24	300.50
Adjustments in respect of Income tax of year 2019-20	59.84	(193.10)
	2,983.08	107.40
MATCredit Entitlement	(1,092.30)	(300.50)
Deferred tax:		
Deferred tax relating to origination and reversal of temporary differences	213.36	288.72
Total expenses reported in the statement of profit or loss	2,104.14	95.62
Total reported in the Statement of Profit and Loss	2,104.14	95.62

Notes on standalone Financial Statement for the year ended 31st March 2022
Note: 31 - Calculation of Earnings per equity share [EPS]:
(Rs. In Lakhs)

Particulars	As at 31 st March	
	2022	2021
The numerators and denominators used to calculate the basic and diluted EPS are as follows:		
A. Profit attributable to Shareholders	846,711,238	165,930,834
B. Numbers Basic and weighted average number of Equity Shares outstanding during the year	50,866,551	50,866,551
C. Basic EPS	16.65	3.26
D. Diluted EPS	16.65	3.26

Note: 32 - Segment Information:

Segment Information has been given in the Consolidated Financial Statements of the Company.

Hence, as per Ind AS-108 Operating Segments issued by the Institute of Chartered Accountants of India, no separate disclosure on segment information is given in these financial statements.

Note: 33 - Contingent liabilities and commitments [to the extent not provided for]:

The Company has given letter of comfort to banks for overdraft and term loan facilities availed by its subsidiary Company. As per the terms of letter of comfort, the Company undertakes to provide such managerial, technical and financial assistance to ensure continues successful operations of the subsidiary.

Note: 34: Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.

Note No. 35 - Related Party Transaction
[Pursuant to Clause (h) of sub-section (3) of Section 134 of the Companies Act, 2013, and Rule 8(2) of the Companies (Accounts) Rules, 2014 – AOC-2]

Name(s) of the Related Party	Nature of Relationship	Nature of contracts/ arrangements/ transactions	Duration of contracts/ arrangements/ transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Date(s) of approval with the Board, if any	Amount Paid as Advance, if any
Dr. Ajay P. Thakker	Managing Director	Remuneration	Ongoing	Remuneration	2016-09-27	No
V. Raghavan	Director	Professional Fees	Ongoing	Professional Fees	2016-09-27	No
Dr. Ankit Thakker	Executive Director	Remuneration	Ongoing	Remuneration	2016-09-27	No
Jupiter Scan & Imaging Centre P. Ltd.	Sister Concern	Rent charges	Ongoing	Rent charges	2015-05-24	No
Jupiter Pharmacy	Partner	Pharmacy Purchase + Rent	Ongoing	Pharmacy Purchase	2015-05-24	No
Entisi	Common Partners	Arrangement	Ongoing	Arrangement	2022-03-08	YES
Jupiter Hospital Projects Private Limited	Subsidiary	Current support	Ongoing	Current support	2022-03-08	YES

Transactions during the year (Rs. In Lakhs)

Pharmacy Purchase	8.80
Advance Arrangement	80.00
Rent Charges	22.50
Professional Fees	49.56
Directors Remuneration	299.88
Subsidiary	2,300.00

NOTES FORMING PART OF THE STANDALONE FINANCIAL STATEMENTS**1. CORPORATE INFORMATION.**

Jupiter Life Line Hospitals Ltd. is a Company running multi-specialty Hospital of 350 beds in Thane near Mumbai and 220 beds in Baner, Pune. Its name is well received in the medical field and is one of the better known addresses for medical treatment in and around Mumbai / Thane / Pune. It has also set up Fortune Park Lake City Hotel in collaboration with ITC group of hotels for promoting medical tourism.

In the year 2020 the company has invested and acquired majority stake in Jupiter Hospital Projects Pvt. Ltd. situated at Indore.

STANDALONE SIGNIFICANT ACCOUNTING POLICIES**a) Statement of compliance**

The financial statements have been prepared in accordance with Ind AS standards notified under the Companies (Indian Accounting Standards) Rules, 2015.

Upto the year ended March 31, 2021, the Group prepared its financial statements in accordance with the requirements of previous GAAP, which includes Standards notified under the Companies (Accounting Standards) Rules, 2006. These are the Group's first Ind AS financial statements.

b) Basis of Accounting

The financial Statements are prepared on accrual basis under the Historical Cost Convention. The accounting policies have been consistently applied unless otherwise stated.

c) Use of Estimates

The preparation of financial statements is in conformity with generally accepted accounting principles which require the management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting periods. Although these estimates are based upon the management's best knowledge of current events and actions, actual results could differ from those estimates and are recognized in the period in which results are known/ materialized.

d) Inventories

The inventories of all medicines, medicare items dealt with by the Company are valued at cost or net realizable value, whichever is lower, applying the FIFO method.

Stock of provisions, stores (including lab materials and other consumables), stationeries and

Housekeeping items are stated at cost or net realizable value, whichever is lower.

Hotel division consists of consumable items which are all valued at cost or net realizable value, whichever is lower.

Cost includes all costs of purchase, and other costs incurred in bringing the inventories to their present location and condition inclusive of non-refundable (adjustable) taxes wherever applicable.

e) Revenue Recognition

In Hospital revenue comprises primarily comprise fees charged for inpatient and outpatient hospital services. Services include charges for accommodation, theatre, medical professional services, equipment, radiology, laboratory and pharmaceutical goods used. Revenue is recorded and recognized during the period in which the hospital service is provided, based upon the estimated amounts due from patients and/or medical funding entities. Unbilled revenue is recorded for the service where the patients are not discharged and invoice is not raised for the service.

The patient is obligated to pay for healthcare services at amounts estimated to be receivable based upon the Company's standard rates or at rates determined under reimbursement arrangements. The reimbursement arrangements are generally with third party administrators. The reimbursement is also made through national, international or local government programs with reimbursement rates established by statute or regulation or through a memorandum of understanding.

In Hotel Division revenue is recognized on accrual basis.

Dividend income from investments is recognised when the shareholder's right to receive payment has been established (provided that it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably).

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable

f) Property, plant and equipment

Freehold land is carried at cost. Fixed Assets are stated at cost net of recoverable taxes, trade discounts, and rebates, if any, less accumulated depreciation. The cost includes purchase price and any cost directly attributable to bring the Asset to its working condition for its intended use.

Depreciation: Depreciation on Tangible Fixed Assets is provided on Straight Line Method (SLM) based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013. Intangible Fixed Assets are amortized over a period of 5 years. In Fortune Park Hotel division included stock in circulation like crockery, cutlery, linen, uniform or glass wares which have been charged off to Profit & Loss A/c based on estimates made by Management

Advances paid towards acquisition of property, plant and equipment outstanding at each Balance Sheet date, are shown under other non-current assets and projects under which assets are not ready for intended use are disclosed under Capital Work-in-Progress. Capital Work-in-Progress includes the additional department being set up at Pune and Thane.

As on 31/03/2022

CWIP	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in Progress	885.59	0.80	499.30	-	1,385.69
Projects temporarily suspended	-	-	-	-	
Total	885.59	0.80	499.30	-	1,385.69

As on 31/03/2021

CWIP	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in Progress	394.06	-	843.17	96.22	1,333.45
Projects temporarily suspended	-	-	-	-	-
Total	394.06	-	843.17	96.22	1,333.45

g) Lease Assets

Lease is considered as financial lease when lessor transfers substantially all the risk & rewards incidental to ownership of an asset i.e. when lessee has an option to purchase the asset at a price which is insufficiently lower than the fair market value and/or term of lease is for substantial part of economic life of the asset. Otherwise lease is considered as operating lease. Rentals under operating lease are expensed on a straight line basis with reference to the lease terms and other considerations.

h) Employee benefits

Regular contributions are made to the State administered Provident Fund which is charged against revenue.

Provident fund

The Company contributes to the statutory provident fund of the Regional Provident Fund Commissioner, in accordance with Employees provident fund and Miscellaneous Provision Act, 1952. The plan is a defined contribution plan and contribution paid or payable is recognized as an expense in the period in which the employee renders services.

Gratuity

Gratuity Fund is maintained with the Life Insurance Corporation (LIC) of India on the basis of valuation done by LIC to discharge the gratuity liability to the employee.

Other short-term benefit

All employee benefits falling due within twelve months of the end of the period in which the employees render the related services are classified as short-term employee benefits, which include benefits like salaries, wages, short term compensated absences, performance incentives, medical insurance etc. and are recognised as expenses in the period in which the employee renders the related service and measured accordingly.

i) Foreign Currency Transactions:

Transactions denominated in foreign currency are generally recorded at the exchange rate prevailing on the date of the transaction.

Exchange difference if any arising on the settlement of monetary dues or on reporting the company's monetary items at rates different from those at which they were initially recorded during the year or, reported in previous financial statements are recognized as respective assets and / or income or expense in the year in which they arise.

j) Earning per Share:

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity share holders by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all potential equity shares.

k) Dues to Micro and Small Enterprises:

This information is required to be disclosed under the Micro, Small and Medium enterprises Development Act 2006. It has to be determined to the extent such parties have been identified on the basis of information available with the Company. In the absence of intimation/Information from the concerned parties the required information could not be extracted.

l) Taxes on Income:

Tax expense comprises of current tax and deferred tax. Current tax is measured at the amount expected to be paid to the income tax authorities, using the applicable tax rates. Deferred income tax reflect the current period timing differences between taxable income and accounting income for the period and reversal of timing differences of earlier periods. Deferred tax assets & liabilities are measured using the tax rates and tax law that have been enacted by the balance sheet date. Provision for Deferred Tax Liability is made to take care of timing difference in tax treatment of various expenses but mainly of depreciation.

m) Contingent Liability:

Contingent Liabilities are possible but not probable obligations as on Balance Sheet date, based on the available evidence. There are no such contingent liabilities which require disclosure.

n) Segment Reporting:

The Company is not required to disclose separately segment reporting as regards Hotel division in financial statement as per Ind AS 108 because it's Revenue, Profit & Loss and Assets are not exceeding 10% of Total Revenue, Profit & Loss and Assets of Company.

o) Cash and cash equivalents:

Cash and cash equivalents include cash in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less.

Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the company are segregated.

p) Borrowing cost:

All capital assets during the year have been acquired out of self generated funds. No borrowing costs are attributed to acquisition on new assets. Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months after the reporting date.

All other borrowing costs are recognized in statement of profit and loss in the period in which they are incurred.

q) Promoter Shareholding

Shares held by the Promoters at the end of the Year 2022				% Change During The Year
Sr No	Promoter's Name	No. of Shares	% of Total Shares	
1	DR. AJAY P THAKKER	81,23,329	15.97%	NIL

Shares held by the Promoters at the end of the Year 2021				% Change During The Year
Sr No	Promoter's Name	No. of Shares	% of Total Shares	
1	DR. AJAY P THAKKER	81,23,329	15.97%	NIL

r) Trade Receivables

As on 31/03/2022

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 m	6m - 1 yr	1-2 yrs	2-3 yrs	More than 3 yrs	
Undisputed Trade receivables considered good	2,047.21	278.03	274.01	98.69	67.07	2,765.02
Undisputed Trade Receivable which have significant increase in credit risk	-	-	-	-	-	-
Undisputed Trade Receivable credit impaired	-	-	-	-	-	-
Disputed Trade receivables considered good	-	-	-	-	-	-
Disputed Trade Receivable which have significant increase in credit risk	-	-	-	-	-	-
Disputed Trade Receivable credit impaired	-	-	-	-	-	-

As on 31/03/2021

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 m	6m - 1 yr	1-2 yrs	2-3 yrs	More than 3 yrs	
Undisputed Trade receivables considered good	1,488.40	191.32	168.05	164.15	31.08	2,043.00
Undisputed Trade Receivable which have significant increase in credit risk	-	-	-	-	-	-
Undisputed Trade Receivable credit impaired	-	-	-	-	-	-
Disputed Trade receivables considered good	-	-	-	-	-	-
Disputed Trade Receivable which have significant increase in credit risk	-	-	-	-	-	-
Disputed Trade Receivable credit impaired	-	-	-	-	-	-

s) Trade Payables

As on 31/03/2022

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 yr	1-2 yrs	2-3 yrs	More than 3 yrs	
MSME	-	-	-	-	-
Others	4,968.92	264.17	58.78	70.17	5,362.04
Disputed Dues - MSME	-	-	-	-	-
Disputed Dues - Others	-	-	-	-	-

As on 31/03/2021

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 yr	1-2 yrs	2-3 yrs	More than 3 yrs	
MSME	-	-	-	-	-
Others	4,187.56	198.15	292.48	292.26	4,970.45
Disputed Dues - MSME	-	-	-	-	-
Disputed Dues - Others	-	-	-	-	-

t) Disclosure of Ratios

Ratio	Numerator	Denominator	Current Period	Previous Period	% Variance	Reason For Variance
Current ratio	17,642.10	10,329.96	1.71	1.32	0.39	-
Debt-Equity	29,787.63	32,887.31	0.91	1.02	-0.11	-
Debt service coverage ratio	14,156.35	3,225.30	4.39	1.79	2.60	-
Return on equity ratio	8,467.11	32,887.31	0.26	0.07	0.19	-
Inventory turnover ratio	66,103.30	1,241.10	53.26	36.49	16.78	-
Trade receivables turnover ratio	46,009.50	2,404.01	19.14	9.93	9.21	-
Trade payables turnover ratio	12,841.76	5,166.24	2.49	1.70	0.79	-
Net capital turnover ratio	66,103.30	32,887.31	2.01	1.84	0.17	-
Net profit ratio	8,467.11	66,103.30	13%	4%	9%	-
Return on capital employed	13,494.62	65,144.63	21%	9%	12%	-
Return on investment	242.73	15,171.72	2%	1%	1%	-

2. First-time adoption – mandatory exceptions, optional exemptions

The Company has prepared the opening balance sheet as per Ind AS as of April 1, 2020 (the transition date) by recognizing all assets and liabilities whose recognition is required by Ind AS, not recognizing items of assets or liabilities which are not permitted by Ind AS, by reclassifying items from previous GAAP to Ind AS as required under Ind AS, and applying Ind AS in measurement of recognized assets and liabilities. However, this principle is subject to the certain exception and certain optional exemptions availed by the Company as detailed below:

Deemed cost for Property, Plant and Equipment, Investment Property, and Intangible Assets:

has elected to continue with the carrying value of all of its property, plant and equipment recognized as of April 1, 2015 (transition date) measured as per the previous GAAP and use that carrying value as its deemed cost as of the transition date.

3. SUBSIDIARIES:

The Company has invested in Jupiter Hospital Projects Pvt. Ltd. holding 76% stake as on 31/03/2022. The total paid up capital of the Company consists of Rs. 50 Crores Equity Shares capital and Rs. 30 Crores Optionally Convertible Redeemable Preference Shares Capital out of which the Company is holding Rs. 38 Crores Equity share capital and Rs.30 Crores OCRPS Capital respectively. The Company has prepared the consolidated financial statements which form part of this Annual Report. Further, a statement containing the salient features of the financial statement of our subsidiaries in the prescribed format AOC -1 is appended as annexure 3 to the board's report.

**As per our report of even date
For B. R. Kotecha & Co.
Chartered Accountants
Firm's Registration No.105283W**

Sd/-

**B.R.Kotecha
(Proprietor)
Membership No.036309
04/07/2022
Mumbai
UDIN: 22036309AMJQZB9972**

Sd/-
**Dr. Ajay P Thakker
Managing Director**

Sd/-
Chief Financial Officer

**For and on behalf of the Board of Directors of
Jupiter Lifeline Hospitals Limited**

Sd/-
**Dr. Navinchandra Davda
Director**

Sd/-
Company Secretary

Eastern Express Highway, Thane (W)

Call: 022 2172 5555


Jupiter Hospital
Patient First
